Clinical Trials
25 trialsNCT05100862 2026-05-27
MAHOGANY
BeOne Medicines
Phase 3 Recruiting
NCT06911502 2026-05-20
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene
Phase 3 Recruiting
NCT03937635 2026-05-15
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT04566328 2026-05-15
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Eastern Cooperative Oncology Group
Phase 3 Recruiting
NCT05623020 2026-05-14
MagnetisMM-6
Pfizer
Phase 3 Recruiting
NCT06182774 2026-05-12
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT05438043 2026-05-08
A Study of Daratumumab
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT05552222 2026-05-08
MajesTEC-7
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06149286 2026-05-06
OLYMPIA-5
Regeneron Pharmaceuticals
Phase 3 Recruiting
NCT06191744 2026-05-06
EPCOREâ„¢FL-2
Genmab
Phase 3 Recruiting
NCT06084936 2026-05-04
GLOBRYTE
Hoffmann-La Roche
Phase 3 Recruiting
NCT06679101 2026-04-22
DREAMM-10
GlaxoSmithKline
Phase 3 Recruiting
NCT06918002 2026-04-02
ElLen
Intergroupe Francophone du Myelome
Phase 3 Recruiting
NCT05243797 2026-03-25
MajesTEC-4
European Myeloma Network B.V.
Phase 3 Recruiting
NCT06932562 2026-03-25
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
European Myeloma Network B.V.
Phase 3 Recruiting
NCT05827016 2026-03-13
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
Bristol-Myers Squibb
Phase 3 Recruiting
NCT07297329 2026-01-29
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Sinocelltech Ltd.
Phase 3 Recruiting
NCT06220032 2026-01-05
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT06006117 2025-12-19
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT06082102 2025-09-15
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3 Recruiting
NCT05561387 2025-06-04
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06284122 2024-10-15
MorningLyte
The Lymphoma Academic Research Organisation
Phase 3 Recruiting
NCT06187441 2024-08-19
HOVON174MM
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT06522555 2024-08-05
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
Ruijin Hospital
Phase 3 Recruiting
NCT05351346 2023-03-24
Genotype-guided Treatment in DLBCL
Ruijin Hospital
Phase 3 Recruiting